AAAP’s 2022 Addictions and Their Treatment
Disclosure to Learners Statement

In accordance with the disclosure policy of the American Academy of Addiction Psychiatry, as well as standards set forth by Joint Accreditation for Interprofessional Continuing Education policies and accreditation requirements including the Standards for Integrity and Independence in Accredited Continuing Education, AAAP is expected to present learners with unbiased, independent, and objective information in all of our activities. Therefore, Member(s), Author(s), Reviewer(s), and all others involved in the planning or content development of this activity must disclose all financial and professional relationships within the past 24 months. These disclosures have been reviewed and all relevant relationships have been mitigated.

The following planner has relevant relationships to disclose:

- Michelle Lofwall, MD
  - Titan Pharmaceuticals
  - Consultant
- Kevin Sevarino, MD, PhD
  - GlaxoSmithKline
  - Stock

All others involved in the planning and presentation of this activity have no relevant relationships to disclose.

All speakers have been advised that any recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in the presentation must conform to the generally accepted standards of experimental design, data collection, and analysis.

AAAP has mitigated all relevant relationships.